ANGPTL4 and coronary artery disorder: In conclusion, our genetic analysis predicts that in a broader dyslipidaemic patient population, therapies aimed at decreasing plasma ANGPTL3, ANGPTL4, or APOC3 levels will be effective in preventing CAD without raising specific safety concerns.